Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol

被引：0
|
作者：
Ditte Hansen
Lisbet Brandi
Knud Rasmussen
机构：
[1] Roskilde Hospital,Medical Department
[2] University of Copenhagen,Department of Surgery and Internal Medicine
来源：
BMC Nephrology | / 10卷
关键词：
Chronic Kidney Disease; Hypercalcemia; Vascular Calcification; Secondary Hyperparathyroidism; Alfacalcidol;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Budget impact analysis of the use of paricalcitol for the treatment of secondary hyperparathyroidism in chronic kidney disease
    Lorenzoni, Valentina
    Turchetti, Giuseppe
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2014, 15 (03) : 71 - 80
  • [32] Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD
    Coyne, D
    Acharya, M
    Qiu, P
    Abboud, H
    Batlle, D
    Rosansky, S
    Fadem, S
    Levine, B
    Williams, L
    Andress, DL
    Sprague, SM
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2006, 47 (02) : 263 - 276
  • [33] Long-term therapy with paricalcitol for secondary hyperparathyroidism in hemodialysis patients
    Pai, AB
    Lin, S
    Arruda, JAL
    Lau, AH
    INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2003, 26 (06) : 484 - 490
  • [34] Treatment of secondary hyperparathyroidism with paricalcitol in patients with end-stage renal disease undergoing hemodialysis in Turkey: an observational study
    Koc, Hasan
    Hoser, Hasan
    Akdag, Yalcin
    Kendir, Cemaliye
    Ersoy, F. Fevzi
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2019, 51 (07) : 1261 - 1270
  • [35] PARICALCITOL IN SECONDARY HYPERPARATHYROIDISM AND THE SURVIVAL BENEFIT IN PATIENTS WITH CHRONIC KIDNEY DISEASE
    Al-Baaj, Fouad
    Yadav, Punit
    Al-Rifai, Adriece
    JOURNAL OF RENAL CARE, 2011, 37 (02) : 75 - 79
  • [36] Paricalcitol Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients: A German-Austrian, Single-Arm, Open-Label, Prospective, Noninterventional, Observational Study
    Biggar, Patrick
    Kovarik, Josef
    Klauser-Braun, Renate
    Graf, Helmut
    Mueller, Hans-Walter
    Veres, Andras
    Seidinger, Susanne
    Ketteler, Markus
    NEPHRON CLINICAL PRACTICE, 2014, 126 (01): : 39 - 50
  • [37] Effects of cinacalcet treatment on serum soluble Klotho levels in haemodialysis patients with secondary hyperparathyroidism
    Komaba, Hirotaka
    Koizumi, Masahiro
    Tanaka, Hisae
    Takahashi, Hiroo
    Sawada, Kaichiro
    Kakuta, Takatoshi
    Fukagawa, Masafumi
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 (05) : 1967 - 1969
  • [38] Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism
    Jamaluddin, Ema J.
    Gafor, Abdul Halim Abdul
    Yean, Loo Chee
    Cader, Rizna
    Mohd, Rozita
    Kong, Norella C. T.
    Shah, Shamsul Azhar
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2014, 18 (03) : 507 - 514
  • [39] Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide
    Cozzolino, Mario
    Galassi, Andrea
    Conte, Ferruccio
    Mangano, Michela
    Di Lullo, Luca
    Bellasi, Antonio
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2017, 13 : 679 - 689
  • [40] Efficacy and initial dose determination of paricalcitol for treatment of secondary hyperparathyroidism in Chinese subjects
    Yan, Yucheng
    Qian, Jiaqi
    Chen, Nan
    Huang, Zhaoxing
    Jiang, Gengru
    Li, Xuewang
    Lin, Hongli
    Liu, Liqiu
    Wang, Mei
    Xing, Changying
    Yu, Xueqing
    Zuo, Li
    Amdahl, Michael
    Khan, Samina
    CLINICAL NEPHROLOGY, 2014, 81 (01) : 20 - 29
12345